Pharmacies and clinics on wheels? That’s the premise behind the growing effort by retail pharmacy and clinic providers to expand their reach via specially equipped buses and other vehicles that provide on-the-spot, temporary access to needed health services in hundreds of communities nationwide.

Thank you to the 114th Congress for welcoming the participants in the 2015 NACDS RxIMPACT Day on Capitol Hill! We appreciate the opportunity to meet with you and discuss the key policy issues that shape pharmacy patient care for your constituents.

The value of collaboration through the National Association of Chain Drug Stores was on display Monday, as the NACDS Regional Chain Conference explored business-to-business partnerships and a public policy agenda that benefits patients and consumers.

AmerisourceBergen on Friday announced that Ornella Barra, EVP Walgreens Boots Alliance and president and CEO of global wholesale and international retail has been elected to its board of directors, effective immediately.

With tens and possibly hundreds of billions of dollars in potential savings still snagged in a regulatory limbo, federal lawmakers and health industry stakeholders strongly urged the Food and Drug Administration last month to knock down the final barriers to review and approval of biosimilar drugs for marketing in the United States.

The pharmaceutical industry is back. Fueled by the launch of expensive, new biotech medicines, rising prices for both branded and generic drugs and a recent slowdown in branded-drug patent expirations and generic competition, the U.S. pharmaceutical market is staging a remarkable resurgence.

Are high distribution costs and overly complex regulations stifling pharmaceutical and health product suppliers’ ability to fully engage with the fast-changing healthcare marketplace? That’s one concern raised by a global survey of healthcare executives in the United States, Canada, Europe, Asia and Latin America from United Parcel Service.

After a recent spike in the prices charged for some generic drugs led to outcries from pharmacists, patient advocates and federal lawmakers, a report issued last month suggests that drug costs can be controlled if the Food and Drug Administration changes the way it handles reviews and approvals.

Thirty years ago, Democratic and Republican members of Congress hammered out a rare and prescient bipartisan compromise bill that transformed the pharmaceutical landscape forever and unleashed the modern generic drug industry. That law, known as the Hatch-Waxman Act, has proven to be one of the most far-reaching and impactful pieces of legislation ever to shape the American healthcare system.

The response to the current global Ebola scare from both the pharmaceutical and pharmacy industries has been nothing short of remarkable. Precautionary preparations have been made to address the Ebola concerns in the United States; several pharmaceutical manufacturers have been working around the clock toward an Ebola vaccine and treatment; and there has been an outpooring of goods that have been directed to help with the outbreak in West Africa.

Ebola is not a problem in the United States, at least not yet (nor hopefully will it ever be), but the pharmaceutical community is stepping up to help around the world. And in the U.S., there is much being done to help the pharmacy world prepare.